Therefore, the current study objective was to generate and characterize a novel CD19-directed antibody therapeutic based on a humanized CD19-IgG1 antibody and fused with the apoptosis-inducing ligand TRAIL, in order to induce BCP-ALL-specific killing. Here, TNFSF10 is linked to acute lymphoblastic leukemia.